Roche Holdings AG (OTCQX:RHHBY) on Tuesday said it received European CE Mark approval for Elecsys pTau217, a blood test designed to help detect amyloid pathology linked to Alzheimer's disease earlier in patients showing signs of cognitive decline.

Roche Wins CE Mark For Alzheimer's Blood Test

Eli Lilly and Co. (NYSE:LLY) collaborated with Roche to develop the test to measure phosphorylated Tau 217 protein, or pTau217, a biomarker associated with Alzheimer's pathology.

Roche said the same high and low cutoff values can be applied across both primary and secondary care settings to help clinicians rule in or rule out amyloid pathology in patients reporting memory or cognitive concerns.

Roche And Lilly Highlight Need For Earlier Diagnosis

According to Roche, early identification of amyloid pathology can help patients, families, and caregivers better understand symptoms and access appropriate care sooner.

"Today, many people face a long and difficult path to a diagnosis," said Matt Sause, CEO of Roche Diagnostics. He added ...